Navigation Links
Pipeline of Atrial Fibrillation Therapeutics for H2 2015 Studied in New Research Report
Date:11/23/2015

PUNE, India, November 23, 2015 /PRNewswire/ --

New market research "Atrial Fibrillation - Pipeline Review, H2 2015" covers global therapeutic landscape of Atrial Fibrillation and reviews key pipeline products under drug profile section which include product description, MoA and R&D brief, licensing and collaboration details & other developmental activities.

Complete report on Atrial Fibrillation Pipeline Review spread across 107 pages with 35 tables and 15 figures is now available at http://www.reportsnreports.com/reports/440484-atrial-fibrillation-pipeline-review-h2-2015.html .

This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this report include ARCA biopharma, Inc., Armetheon, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Cardiome Pharma Corp., Daiichi Sankyo Company, Limited, Gilead Sciences, Inc., Isis Pharmaceuticals, Inc., Laboratoires Pierre Fabre SA, Nissan Chemical Industries, Ltd., Nyken BV, Otsuka Holdings Co., Ltd. and Xention Limited. Drug Profiles mentioned in this report are AT-300, BMS-394136, BMS-919373, bucindolol hydrochloride, budiodarone, edoxaban tosylate, F-373280, ISIS-CRPRx, NIP-151, NYK-1112, OMT-33, OPC-108459, ranolazine ER, Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation, Small Molecule to Block Kv1.5 for Atrial Fibrillation, Small Molecule to Block Kv1.5, Nav1.5, IKACh for Atrial Fibrillation, Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation, vanoxerine, vernakalant hydrochloride, XEN-R0702, XEND-0103, XENR-0703 and XENR-0706.

Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=440484 .

Scope of this report: The report reviews key players involved in the therapeutics development for Atrial Fibrillation and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Atrial Fibrillation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Atrial Fibrillation pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Another newly published market research titled Myocardial Infarction - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Myocardial Infarction Pipeline Review research report of 333 pages is available at http://www.reportsnreports.com/reports/435358-myocardial-infarction-pipeline-review-h2-2015.html .

Explore more reports on Pharmaceuticals market available with ReportsnReports.com.

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com



'/>"/>
SOURCE ReportsnReports
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Sepsis Pipeline Review and Epidemiology Forecasts in New Market Research Reports
2. Pipeline of Ischemic Stroke Reviewed in New Market Research Report for H2 2015
3. Oligodendroglioma Pipeline Products / Drug Profiles Reviewed in H2 2015 Report
4. Juniper Pharmaceuticals Adds Three New Products to its Proprietary Pipeline
5. Global Frontier Pharma Report 2015: Versatile Innovation in Oncology - A Number of Highly Promising First-in-Class Versatile Oncology Pipeline Targets
6. Pulmatrix Reports 3rd Quarter Results; Provides Update on Business & Development Pipeline
7. Myelofibrosis Pipeline Therapeutics Reviewed for H2 2015 in New Research
8. Therapeutic Pipeline of Portal Hypertension Reviewed for 2015 in New Market Research Report
9. Anthrax - Pipeline Review, H2 2015
10. Dental Biomaterials - Pipeline Review, 2015
11. Sumitomo Dainippon Pharma Co., Ltd. - Product Pipeline Review - 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2019)... (PRWEB) , ... October 18, 2019 , ... Beginnings Treatment ... to act as the official sponsor of the Alcohol and Other Drug Awareness ... to empower students to make informed decisions around alcohol and other drugs through individual ...
(Date:10/19/2019)... ... October 19, 2019 , ... A popular performer and ... of educational programming. "Behind the Scenes" with Laurence Fishburne has the goal of educating ... large today. Recently, the show has turned its attention to the world of healthcare. ...
(Date:10/17/2019)... ... ... prominent features on a person is the ears. There are times when people are born ... This can cause a great deal of embarrassment to teens as well as adults so ... In order to help patients get the change they desire when it comes to the ...
Breaking Medicine Technology:
(Date:10/19/2019)... ... ... Today, Guide Dogs for the Blind (GDB), the national nonprofit ... people, guide dogs and communities, kicks off the organization’s momentous, weekend-long 2019 Guide Dogs ... community for the event to celebrate GDB’s mission and to experience what the city ...
(Date:10/17/2019)... ... October 17, 2019 , ... Knotty Roller, the affordable all-in-one muscle recovery ... campaign goal– raising more than $20,000 in only eleven hours after launching on ... be the first to enjoy the ease of use and versatility of our product,” ...
(Date:10/17/2019)... ... October 17, 2019 , ... A clinical article reviewing the ... Cosmetic Surgery Paper Award at Plastic Surgery - The Meeting 2019 in San Diego ... 6 Years,” was authored by Larry S. Nichter, M.D., Robert A. Hardesty, M.D., and ...
(Date:10/15/2019)... ... October 14, 2019 , ... Khalieghya Dandie-Evans, a liver ... ride atop the Donate Life Rose Parade® float in the 131st Rose Parade® on ... tissue donation across Northern California and Northern Nevada, the organization’s service area. , Khalieghya, ...
(Date:10/15/2019)... CHURCH, Va. (PRWEB) , ... October 15, 2019 ... ... Products:, Complying with FDA’s Most Recent IFU Guidance , **An FDAnews Webinar**, Tuesday, ... the recent Instructions for Use (IFU) guidance have on new drug applications and ...
Breaking Medicine News(10 mins):